Oramed Pharmaceuticals Inc (ORMP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $161.33M
Last updated: Nov 17, 2026 at 11:05 AM ET
Oramed Pharmaceuticals Inc (ORMP) Stock Forecast
Analysts expect Oramed Pharmaceuticals (ORMP) to earn $4.47 per share in the fiscal year ending Dec 31, 2026. For the quarter ending Dec 31, 2026, the EPS consensus is $0.38.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
- Fiscal year ending Dec 31, 2026
- $4.47
- EPS consensus
- Next report
- Mar 24, 2027
- Estimated
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | $4.47 | $4.47 to $4.47 | 1 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | $0.38 | $0.36 to $0.39 | 3 |
EPS Trend
Over the last 60 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 93.5% from $2.31.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $4.47 | $2.31 | $2.31 | $2.31 | N/A | N/A |
Frequently Asked Questions About ORMP
What is the ORMP stock forecast?
Consensus analyst estimates put Oramed Pharmaceuticals's EPS at $4.47 for the fiscal year ending Dec 31, 2026.
What EPS do analysts expect from ORMP next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $4.47, with estimates from $4.47 to $4.47 from 1 analyst.
How many analysts cover ORMP?
1 analyst estimates EPS for Oramed Pharmaceuticals for the fiscal year ending Dec 31, 2026.
ORMP pages: Overview, Earnings, Forecast, Financials, Competitors